“Existing technologies will not deliver the breakthrough performance required to realize the full potential of the DNA economy … something different, and truly innovative is required.”
— Paul Mola, CEO and Founder
The Story Behind Roswell
The name Roswell was inspired by the "out-of-this-world" disruptive and game-changing nature of our technology. Our technology is based on the most recent advances in chips and nanotechnology coupled with the always-evolving field of genomics. Before we established Roswell, our team was involved in creating and driving global adoption of sequencing technology to solve some of medicine's biggest challenges, yet we continually encountered the significant hurdles of high cost, workflow complexity and limited accuracy. We knew we'd have to think beyond current technology to finally enable the price point, turn-around time and accuracy needed to unlock the DNA economy. We have done just that.
Our Goal: Precision Medicine
Current prevention and treatment of disease is not precisely tailored to each individual's unique variability in genes, environment and lifestyle. Precision medicine should begin with complete knowledge of the individual's genome, however, current whole-genome DNA sequencing technology is still too costly, too complex and low accuracy to use in precision medicine at the population scale. Roswell's sequencing technology was specifically designed to disrupt the current technologies and deliver an "endgame" sequencing platform, ideal for the future of global precision medicine.
Scientific Advisory Board
Professor Tour is regarded as one of the fathers of Molecular Electronics having lead the effort to make the first molecular circuit, which was heralded by the Journal Science as a Breakthrough of the Year in 2000. Professor Tour advises Roswell on all areas regarding Molecular Electronics including molecular conductors, molecular circuits, and synthetic chemistry for nanotechnology. Professor Tour is an expert in synthetic organic chemistry for diverse applications in nanotechnology and nanoelectronics, and is Director of the Center for Carbon Nanotechnology at Rice University. He has received numerous honors for his pioneering work in molecular electronics and nanotechnology.
Professor Yablonovitch is a world leading expert in quantum electronics, quantum photonics, and nano-scale engineering. Professor Yablonovitch advices Roswell in the fiels of nanotechnology including nano-Electronics, nano-Fabrication, and semiconductors. He has received numerous awards for his fundamental contributions in physics and engineering, including the Isaac Newton Medal and the Edison Medal, two of the highest honors in these fields. He is recognized as one of the fathers of modern photonics and the Inventor of the Photonics Crystal, a foundational technology for semiconductors in communication.
Professor Osher is a world-leading expert in Data Sciences and the development of algorithms for computer simulation and data analysis. He advises Roswell in the area of Informatics, including signal processing, data analysis, algorithms, and data science. He has received many awards for his fundamental contributions to the fields of applied math, computational math, and computer science. Professor Osher is the Director of Special Projects at IPAM, a US National Research Center for Pure and Applied Mathematics. Professor Osher is one of the most widely cited computer scientists in history and is widely recognized as the father of modern signal processing methods.
Professor Church is a world leading expert in the technologies used to study and manipulate the genome, and a pioneer in DNA sequencing technology, genome editing technology, and synthetic biology. He advises Roswell in the area of Genomics, including protein engineering, synthetic biology and genomic technology. He has won numerous awards for his fundamental contributions to genomics, including the Bower Award for Achievement in Science, and the American Society for Microbiology Biotechnology Research Award. Professor Church introduced many of the techniques fundamental to current genome sequencing technology, has cofounded numerous companies in the areas of genomics and genetics, and was one of the originators of the Human Genome Project.
Professor Schmid is an expert in fundamental processes of cellular biology. She advises Roswell in the area of Molecular Biology, including protein engineering, biochemistry, and molecular conjugation. She is a Distinguished Chair in Cellular and Molecular Biology and Chairman of the Department of Cell Biology at UT Southwestern Medical Center. She was previously Chairman of the Department of Cellular and Molecular Biology at Scripps Research Institute in San Diego. She is a member of the American Academy of Arts and Sciences and President of the American Society for Cell Biology.
Professor Nelson is a leading expert in the development and application of genomic technologies for use in medicine and medical research. He advises Roswell in the area of Medical Applications of Genomics, including genetic disease, clinical sequencing, biomarkers, and drug discovery. Dr. Nelson is credited with inventing the original DNA microarray technology and its applications to genomics at the Brown Lab in Stanford in 1990. This technology provided the foundation for much of modern genomics research, as well as the later development of Next Generation Sequencing technology. Dr. Nelson has done extensive work finding the genes responsible for human inherited disease and cancer, as well as developing genomics-based therapies for genetic disease.
Board of Directors
Until 2011, he served as SVP and President of the Genetic Systems at Life Technologies, an approximately $1B division of a market-leading provider of DNA sequencing systems developed for academic research, applied market segments for human identification, and clinical diagnostics.
Prior to the formation of Life Technologies, Kip served as Senior Vice President of Invitrogen (2005-2008) where he led the ~$650M Biodiscovery division. During his tenure the company became the market-leading developer and provider of tools and enabling technologies for biomedical research involved in molecular biology, proteomics and cellular analysis.
Before joining Invitrogen Corporation, Mr. Miller served as Vice President and General Manager at BD Biosciences from November 1992 to November 2005. During this period, Mr. Miller owned responsibility for the development of BD Biosciences research flow cytometry instrumentation, research immunology reagents and for the company’s Commercial Operations across the Americas.
Currently Mr. Miller is actively involved as an independent board member at Celsee, Biological Dynamics and Tonbo Biosciences.
Smalley is a co-founder of PTK Capital, a family investment fund focused on investing in companies that can significantly benefit the world while assuring economic growth. PTK invests in life science technologies, health and wellness, and new media while attending to ideal business practices including promoting gender equality. Dr. Smalley sits on the board of directors for Equality Now, an international human rights organization focused on women and girls; previously served on Gordon and Sarah Brown's High Level Panel for the Global Campaign for Education; and Roswell Biotechnologies,. She also serves on the scientific advisory board of Stop Breathe and Think, a meditation app that delivers tools for emotional wellbeing including mindfulness and meditation, and co-founded Cell-Ed, a platform to bring basic literacy to adults in underserved populations using mobile phones.
Art continues to be an active investor in early stage private companies engaged in new technologies, with particular focus on healthcare, online education, digital media, and data analytics. Art’s activities in this area began as an investor in and Vice Chairman of Akamai Technologies Inc., a provider of global, high-performance services for the delivery of internet content, streaming media and applications. Prior to this, Art was involved in the formation of New World Communications, which became the largest Fox Broadcasting affiliate group where he also became President, Chief Operating Officer and a Director. Prior career involvements included a founding partner of Apollo Advisors, LP, one of today’s largest private equity firms and EVP and Co-Head of Corporate Finance of Drexel Burnham Lambert.
Art serves as a member of the University of Pennsylvania's Wharton School Board of Overseers and sits on its Executive Committee. Also at Wharton, Art sits on the Board and is the Founding Funder of the Wharton Customer Analytics Initiative, an entity focused on the evolution of data analytics in the corporate world. Other non-profit affiliations include Vice Chairman of the Skirball Cultural Center, a board member of Bet Tzedek, a legal services organization, the Advisory Board for the Milken Institute Center for the Future of Aging, a member of Los Angeles County Economic Development Corporation (LAEDC), a member of the Los Angeles Coalition for the Economy and Jobs and a member of the UCLA Health System Board.
Art Bilger's successful career began with the completion of his B.S. in Economics from the University of Pennsylvania and subsequent MBA from The University of Chicago.